Equillium (EQ) Stock: Buy, Sell, or Hold?
EQ - Equillium, Inc. Common Stock
$1.42
0.06 (4.41%)
▲
5d:
+0.0%
30d:
-12.35%
90d:
-38.79%
BUY
MODERATE Confidence
Analysis Updated: Oct 28, 2026 12:00 AM ET
Earnings: Nov 12, 2026
13d
Get Alerted When EQ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: EQ shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: EQ shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: EQ is currently trading at $1.42, which is considered fair relative to its 30-day fair value range of $1.27 to $1.66.
Technical Outlook: Technically, EQ is in a strong downtrend. Immediate support is located at $1.16, while resistance sits at $1.51. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: EQ scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.56 (+502.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EQ is in a strong downtrend. Immediate support is located at $1.16, while resistance sits at $1.51. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: EQ scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.56 (+502.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.27 -
$1.66
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.4%)
- BULLISH: Trading 502.5% below Wall St target ($8.56)
- BULLISH: Bottoming setup score 63/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.27 -
$1.66
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.16
Resistance Level
$1.51
Current Trend
Strong Downtrend
Technical data as of
Oct 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.99
Wall Street Target
$8.56
(+502.5%)
Revenue Growth (YoY)
-52.3%
Share & Embed Analysis
Last updated: October 28, 2026 10:10 PM ET
Data refreshes hourly during market hours. Next update: 11:10 PM
Data refreshes hourly during market hours. Next update: 11:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EQ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 67 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$18 | 49 HOLD |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
15 analysts |
$108 | 76 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 57 HOLD |